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Striking cell losses occur during late B lymphocyte Results and discussion
A/WySnJ B cells are unresponsive to BLySmaturation [1–3], reflecting BcR-mediated
We tested A/WySnJ mice for representative BLyS-medi-selection coupled with requisites for viability
ated responses [12, 14, 30]. Strain A/WySnJ mice showedpromoting signals [4–11]. How selection and
no significant change in B cell numbers following in vivosurvival cues are integrated remains unclear, but a
BLyS treatment, whereas A/J mice yielded the expectedkey role for B lymphocyte stimulator (BLySTM;
increase (Figure 1, upper panels). Likewise, soluble re-trademark of Human Genome Sciences, Inc.) is
combinant BLyS (rBLyS) afforded no enhancement ofsuggested by its marked effects on B cell numbers
anti-IgM-induced proliferation among mature (CD23)and autoantibody formation [12–18] as well as the
A/WySnJ B cells in vitro, despite distinct effects on A/JB lineage-specific expression of BLyS receptors
mature B cells and similar responses to anti-IgM alone[19–23]. Our analyses of the B cell-deficient A/WySnJ
(Figure 1, middle panels). Finally, mature (CD23)mouse have established Bcmd as a gene
A/WySnJ B cells failed to show the characteristic BLyS-controlling follicular B cell life span [24–27], and
mediated augmentation of in vitro survival (Figure 1,recent reports show Bcmd encodes a novel BLyS
lower panels).receptor [23, 28, 29]. Here we show that A/WySnJ B
cells are unresponsive to BLyS, affording
Bcmd determines fitness to compete for survivalinterrogation of how Bcmd influences B cell
in the peripheryhomeostasis. Mixed marrow chimeras indicate
The reduced life span of peripheral B cells in A/WySnJA/WySnJ peripheral B cells compete poorly for
mice suggested their survival might rely on successfulperipheral survival. Moreover, in vivo BrdU labeling
competition for BLyS-mediated life span promoting activ-shows that (A/WySnJ  BALB/c)F1 B cells have an ity [26]. We therefore analyzed B cell maturation andintermediate but uniform life span, indicating
survival in lethally irradiated (BALB/c A/J)F1 mice thatviability requires continuous signaling via this
received bone marrow from BALB/c (H-2Kd) and either
pathway. Together, these findings establish the A/WySnJ or A/J mice (both H-2 Kk). If the A/WySnJ muta-
BLyS/Bcmd pathway as a dominant mediator of B tion in bcmd renders B cells unfit to compete with cells that
cell survival, suggesting competition for BLyS/ have a normal gene product, then they should comprise an
Bcmd signals regulates follicular B cell numbers. increasingly smaller proportion of the peripheral B cell
pool as reconstitution progresses.
Addresses: *Department of Pathology and Laboratory Medicine,
University of Pennsylvania School of Medicine, Philadelphia,
The numbers and proportions of immature bone marrowPennsylvania 19104, USA. † Department of Biochemistry, University
B cells were similar in the experimental and control groupsof Wisconsin, Madison, Wisconsin 53706, USA. § Human Genome
Sciences, Rockville, Maryland 20850, USA. throughout the experiment (Figure 2, upper panels). The
skewing toward BALB/c-derived B cells may reflect an
Correspondence: Michael P. Cancro intrinsic advantage of BALB/c stem cells to repopulate
E-mail: cancro@mail.med.upenn.edu irradiated recipients, but the results clearly showed suc-
cessful marrow engraftment and equal rates of A/WySnJ-
§These authors contributed equally to this work. and A/J-derived bone marrow B cell genesis, consistent
with our previous findings [24–26].
Received: 20 September 2001
Revised: 25 October 2001 As expected, the splenic Kk B cell proportions were
Accepted: 29 October 2001
also similar in the two types of chimeras at early time
points, reflecting equal rates of splenic B cell seeding.
Published: 11 December 2001 For example, at day 20 posttransfer, about 20% of the
B220 splenocytes in both chimeras were Kk (Figure 2,
Current Biology 2001, 11:1986–1989 lower panels).However, as peripheral B cell reconstitution
proceeded and the effect of the A/WySnJ defect became
0960-9822/01/$ – see front matter manifest, the proportion of Kk B cells in the A/WySnJ  2001 Elsevier Science Ltd. All rights reserved.
BALB/c → CAF1 chimera declined continuously com-
pared to the A/J  BALB/c → CAF1 chimera. By day
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Figure 1
Figure 2
Marrow and splenic B cell development in mixed bone marrow
chimeras. Mixed marrow chimeras were generated by our previously
published procedures [3, 26]. At the indicated times posttransfer,
bone marrow (upper panels) and splenocytes (lower panels) were
harvested and stained with anti-B220, anti-H-2Kd (left panels), and
anti-H-2Kk (right panels). Open bars represent BALB/c 
A/WySnJ → CAF1 chimeras, and closed bars represent BALB/c BLyS responsiveness of A/WySnJ and A/J B cells. (Upper panels)
A/J → CAF1 chimeras. Values are mean  SD.Splenic B cell numbers were determined from mice that had received
either no treatment or 10 g rBLyS s.c. daily for 14 days. Immature
B cells (shaded bars) are IgMhi, B220lo, IgD, while mature B cells
(open bars) are IgM, B220hi, IgD. Results shown are the mean 
SD. (Middle panels) Triplicate cultures of 2  105 mature (CD23) the BLyS/Bcmd pathway influences B cell longevitysplenic cells were treated with the indicated concentrations of F(ab)2 through a deterministic versus probabilistic mechanism.anti-mu, either alone (closed circles) or in the presence of 50 ng/ml
We reasoned that if a fixed, lengthy life span is dictatedsoluble rBLyS (open circles). Tritiated thymidine was added for the
final 18 hr of culture. Data shown are representative of three through a single threshold event received during matura-
experiments and show mean  SD. (Lower panels) Mature splenic tion, then this gene dosage effect indicates approximately
(CD23) B cells were cultured for 72 hr in the presence of medium
half of the B cells in heterozygotes successfully achievealone (filled histograms) or 50 ng/ml rBLyS (thick line). Cells were
this threshold. This deterministic hypothesis predicts thatthen harvested and percent live determined by propidium iodide
exclusion. F1 B cells comprise two pools: those that attained the
requisite threshold and have a long (A/J) life span and
those that failed to attain the threshold and have a short
(A/WySnJ) life span. Alternatively, under a probabilistic
48posttransfer, experimental chimeras had only 3.8% Kk mechanism in which repeated signaling via the Bcmd
splenic B cells compared with 17.4% in the controls (p  pathway maintains B cell viability, all B cells in heterozy-
0.01). These findings establish BLyS/Bcmd signaling as a gotes are similarly fit, and a single pool with intermediate
B cell intrinsic pathway required for longevity and suggest life span is predicted. We therefore assessed the life span,
that competition for these signals determines peripheral renewal, and production rates of mature splenic B cells
B cell life span. in (BALB/c  A/WySnJ)F1 and (BALB/c  A/J)F1 mice
through in vivo BrdU labeling studies. If all F1 B cells have
an intermediate life span, then plotting the proportion ofB cell life span in heterozygotes is uniform
and intermediate BrdU-labeled cells versus time should yield a line whose
monophasic slope is intermediate to those for A/JMice heterozygous for the A/WySnJ defect have interme-
diate numbers of mature peripheral B cells, indicating a andA/WySnJ B cells. In contrast, if F1 B cells comprise
separate short- and long-lived populations, then the plotgene dosage effect (Figure 3, upper panel, and [24,
26]).This observation allowed us to determine whether should be biphasic.
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Figure 3
than bi- or multinomial relationship (Figure 3, lower
panels).
The (BALB/c  A/WySnJ)F1 mature splenic B cells have
a labeling rate that was intermediate to that of the
(BALB/c  A/J)F1 and to that shown previously for
A/WySnJ mature B cells. The time to label 50% of cells
was calculated to be 60 days compared to 80 days for
(BALB/c  A/J)F1 and 37 days for A/WySnJ. The calcu-
lated half-life of mature B cells from (BALB/c 
A/WySnJ)F1 mice was 86 days, compared to 121 and 51
days for (BALB/c  A/J)F1 and A/WySnJ mice, respec-
tively [26].
These results, coupled with our previous studies, provide
insight regarding how BLyS regulates peripheral B cell
numbers. For example, past BrdU labeling studies re-
vealed markedly shortened life span in all A/WySnJ
splenic B2 but not B1 subsets, indicating a primary role
in the survival of developing and quiescent B2 cells [26,
27]. The results herein further disclose a fundamental
and dominant role for this pathway in peripheral B cell
homeostasis. Since B cell genesis rates are identical in A/J
and A/WySnJ mice [26], these findings confirm that B cell
life span is normally the primary determinant of peripheral
pool size [32]. Moreover, they show that B cell life span
is not determined by a single threshold event duringmatu-
ration, because the intermediate steady-state numbers of
(A/WySnJ  BALB/c)F1 B cells do not reflect separate
populations of long- and short-lived cells. One interpreta-Analysis of BrdU labeling rates among mature peripheral B cells in
A/WySnJ and F1 mice. (Upper panel) The numbers of splenic B tion of these data might be that a single, BLyS-mediated
cells expressing each parental IgH allele were determined in parental signal of intermediate strength is received as cells transit
and F1 mice. Open bars indicate B220 splenocytes staining with anti- to the mature pool, thereby imparting intermediate life
IgMa-specific antibodies, and closed bars indicate cells staining with
span. However, mice treated with soluble BLyS receptoranti-IgMe-specific antibodies. (Middle panels) Adult (A/WySnJ 
exhibit profound reductions in B cell numbers within 2BALB/c)F1 (circles) and (A/J  BALB/c)F1 (squares) mice were treated
with BrdU and the labeling kinetics of splenic B cell subsets weeks of treatment [18], a timeframe too short to be
determined [3, 26]. Both the proportional (left plot) and absolute (right accommodated by senescent attrition among mature B
plot) BrdU labeling rates among mature splenic (B220hiHSAlo) B cells
cells, whose half-life is 80–120 days [3, 26, 33, 34]. In-are shown. Lines predicted by least squares regression are
stead, we favor the notion that continuous signaling viasuperimposed. Since these populations are nondividing and thus
do not commence labeling with the onset of BrdU treatment, no the BLyS/Bcmd pathway is required formature peripheral
assumptions of origin were made. Dashed lines and filled squares B cell survival, yielding a stochastic competition model
correspond to the (A/WySnJ  BALB/c)F1 regression and data points, for peripheral B cell life span. While likely complex, thewhereas dotted lines and filled circles correspond to the (A/J 
mechanisms underlying BLyS-mediated survival amongBALB/c)F1. The solid line shows the labeling rates of A/WySnJ mice
previously determined [26] and is included here for comparison. peripheral B cells probably include regulation of Bcl-2
(Lower panels) The residuals of the absolute labeling rate regression family members [35–37]. Ongoing analyses indicate BLyS
lines determined for each set of F1 mice, as well as the least squares directly influences several members of this gene family,regression of these residuals, are shown.
including A1 and Bcl-xL, but that the exact effects differ
depending on maturation stage and relative expression
of the various BLyS receptors (B.L.H., S.M.H. et al.,
unpublished data).The plots clearly suggested a monophasic rather than
biphasic increase in the proportion and numbers of labeled
cells over time (Figure 3, middle panels). This interpreta- We previously suggested the A/WySnJ defect could either
enhance negative or attenuate positive selection. Sincetion was validated by plotting residual errors [31], which
showed the expected random dispersal around the pre- the size and survival of immature as well as mature B cell
subsets are affected (Figure 1 and [26]), it is tempting todicted line. Moreover, a regression line for the residual
plot was horizontal, further substantiating a linear, rather speculate that BLyS/Bcmd signals impact both processes
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